Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 7;6(1):17.
doi: 10.3390/biomedicines6010017.

Photodynamic Therapy in Ocular Oncology

Maria Antonietta Blasi  1 , Monica Maria Pagliara  2 , Angela Lanza  3 , Maria Grazia Sammarco  4 , Carmela Grazia Caputo  5 , Gabriela Grimaldi  6 , Andrea Scupola  7
Affiliations
Review

Photodynamic Therapy in Ocular Oncology

Maria Antonietta Blasi et al. Biomedicines. .

Abstract

Although introduced for the treatment of maculopathies, photodynamic therapy (PDT) is now largely used in some eye cancers treatment. The selective tissue damage with PDT is achieved by sequestration of the photosensitizer in the target tissue and focal activation of the photosensitizer by low energy directed light. In this way, it is possible to achieve the destruction of the tumor tissue by safeguarding the surrounding healthy structures. Our study describes the clinical uses and efficacy of photodynamic therapy in ocular oncology.

Keywords: PDT; choroidal hemangioma; ocular tumors; photodynamic therapy (PDT); uveal melanoma; uveal metastases; vasoproliferative tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Reeves B.C., Harding S.P., Langham J., Grieve R., Tomlin K., Walker J., Guerriero C., Carpenter J., Patton W.P., Muldrew K.A., et al. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: Cohort study for the UK. Health Technol. Assess. 2012;16:1–200. doi: 10.3310/hta16060. - DOI - PubMed
    1. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol. 1999;117:1329–1345. doi: 10.1001/archopht.117.10.1329. - DOI - PubMed
    1. Bressler N.M., Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 2001;119:198–207. - PubMed
    1. McLaughlin C.C., Wu X.C., Jemal A., Martin H.J., Roche L.M., Chen V.W. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–1007. doi: 10.1002/cncr.20866. - DOI - PubMed
    1. Shammas H.F., Blodi F.C. Prognostic factors in choroidal and ciliary body melanomas. Arch. Ophthalmol. 1977;95:63–69. doi: 10.1001/archopht.1977.04450010065005. - DOI - PubMed

LinkOut - more resources